ArticleInvestigative ophthalmology & visual science2025
PCARE-Associated Retinopathy - Genetics, Clinical Characteristics, and Natural History.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal Behavior of the Hyper-Reflective Ganglion Cell Layer Band and Its Association With Ellipsoid Zone Constriction Rate in RP.Investigative ophthalmology & visual science · 2026Article
- Cone-Rod DystrophyDiagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to describe the mutational landscape, clinical characteristics, and natural history of PCARE-associated retinopathy. Methods: Retrospective cohort study including 28 patients (56 eyes) affected by an inherited retinal disease related to PCARE variants. The main outcome measures were best-corrected visual acuity (BCVA) and degree of vision impairment, kinetic visual field (KVF) area delimited with the V4e target, area of macular atrophy (MA) with definitely decreased autofluorescence (DDAF) on short-wavelength autofluorescence, total macular volume (TMV) and foveal sparing (FS) on optical coherence tomography. Results: The median age at first examination was 40.7 years (Interquartile range [IQR] = 28.8-49.6), whereas the median follow-up time was 5.7 years (IQR = 3.6-7.1). The retinal phenotype was consistent with a severe generalized photoreceptor dystrophy with MA in all patients. DDAF lesions were observed in 85% of the eyes. Loss of FS (occurring at a median age of 45 years) was associated with a mean BCVA (logMAR) worsening by 1.1 (95% confidence interval [CI] = 0.6 to 1.5, P < 0.001). Low vision and blindness in the better-seeing eye occurred at median ages of 50 and 57 years, respectively. Longitudinal analysis revealed the following mean slopes of change: BCVA (logMAR) worsened by 0.06/year (95% CI = 0.03 to 0.09, P < 0.001), KVF area decreased by -23%/year (95% CI = -35% to -12%, P = 0.004), square root-transformed DDAF area expanded by 0.20 mm/year (95% CI = 0.16 to 0.23, P < 0.001), and TMV declined by -0.015 mm3/year (95% CI = -0.023 to -0.007, P = 0.003). Eleven novel PCARE variants were identified. Conclusions: PCARE-associated retinopathy is a severe generalized photoreceptor dystrophy with MA. Although visual field loss occurs early, useful central vision is often retained into late adulthood because of FS. Based on the age of onset of legal blindness, the optimal therapeutic window appears to be before the fifth decade of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.